Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GRI-0621

Other · developed by GRI Bio Operations

Phase 3 Most advanced trial
GRI Developer
5 Registered trials

What is GRI-0621?

GRI-0621 is an investigational drug studied in Psoriatic Arthritis, Diabetes, Type I, Chronic Obstructive Pulmonary Disease (COPD).

At a glance

Also known as
Active Comparator
Drug type
Other
Therapy area
Dermatology, Endocrine, Immunology, Infectious disease, Metabolic, Musculoskeletal, Respiratory
Developer
GRI Bio Operations, Inc. (GRI)
Also in trials of
MNKD, PULM, TAK, VALN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06671483 Phase 3 Psoriatic Arthritis Active not recruiting TAK
NCT05298644 Phase 2/3 SARS-CoV-2 Infection Withdrawn VALN
NCT00308308 Phase 3 Diabetes, Type I Completed MNKD
NCT02949375 Phase 2 Chronic Liver Disease Terminated GRI
NCT01921712 Phase 1 Chronic Obstructive Pulmonary Disease (COPD) Completed PULM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Psoriatic ArthritisChronic Liver DiseaseChronic Obstructive Pulmonary Disease (COPD)Diabetes, Type ISARS-CoV-2 Infection

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the GRI page.

Follow GRI, the company behind GRI-0621

See GRI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRI catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.